Sign in to our library of over $5 million worth of researchclose

Two Quick Steps

* Required Fields

Click Your Industry



Registered Customers

If you have an account with us, please log in.

* Required Fields



Subscribe today
Sign in to our library of over $5 million worth of researchclose

Two Quick Steps

* Required Fields

Click Your Industry



Registered Customers

If you have an account with us, please log in.

* Required Fields



Subscribe today

We deliver Mobile Wallet Market Research and SWOT Analysis from Alternative Energy to Pharmaceuticals and Healthcare Market Research Reports to Digital Media.

Skip to Main Content »

Search Site
Researchers Currently Online:1283

Array BioPharma Inc. (ARRY) - Financial and Strategic SWOT Analysis Review

Array BioPharma Inc. (ARRY) - Financial and Strategic SWOT Analysis Review

Double click on above image to view full picture

Zoom Out
Zoom In
Additional Information
Price $125.00
Meta Description Array BioPharma Inc. (Array) is a biopharmaceutical company. The company focuses on the discovery, development and commercialization of targeted small-molecule drugs for treatment of patients with cancer and inflammatory diseases. Its proprietary products
Publisher GlobalData
Date of Report Dec 3, 2013
Quick Overview
Summary

Array BioPharma Inc. (Array) is a biopharmaceutical company. The company focuses on the discovery, development and commercialization of targeted small-molecule drugs for treatment of patients with cancer and inflammatory diseases. Its proprietary products portfolio comprises ARRY-520, ARRY-614, ARRY-797, ARRY-502 and ARRY-981 indicated to treat multiple myeloma, myelodysplastic syndromes, pain, asthma and diabetes. The company's partner programs consist of Selumetinib, MEK162, Danoprevir, AMG 151, ARRY-543/ASLAN001, GDC-0068, LY2603618, GDC-0575, GDC-0425, ARRY-382 and VTX-2337. Array established various collaborations for the development of its product candidates.

Array BioPharma Inc. Key Recent Developments

Feb 04, 2013: Array Reports Revenue Of $18.4m In Q2 Fiscal 2013
Oct 31, 2012: National Jewish Health Researchers Discover New Target For Treatment Of Peanut Allergy
Oct 29, 2012: Array Reports Revenue Of $15.8m In Q1 Fiscal 2013
Aug 13, 2012: Array BioPharma Reports Revenue Of $20.7m In Q4 Fiscal 2012
Apr 30, 2012: Array BioPharma Reports Revenue Of $19.1m In Q3 Fiscal 2012GDPH81714FSA

This comprehensive SWOT profile of Array BioPharma Inc. provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Section 1 - About the Company 5
Array BioPharma Inc. - Key Facts 5
Array BioPharma Inc. - Key Employees 6
Array BioPharma Inc. - Key Employee Biographies 7
Array BioPharma Inc. - Major Products and Services 8
Array BioPharma Inc. - Pharmaceutical Pipeline Products Data 9
Array BioPharma Inc., Pipeline Products by Therapy Area 9
Array BioPharma Inc., Pipeline Products by Development Phase 10
Array BioPharma Inc. - History 12
Array BioPharma Inc. - Company Statement 15
Array BioPharma Inc. - Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Section 2 – Company Analysis 18
Array BioPharma Inc. - Business Description 18
Array BioPharma Inc. - Corporate Strategy 19
Array BioPharma Inc. - SWOT Analysis 20
SWOT Analysis - Overview 20
Array BioPharma Inc. - Strengths 20
Strength - Comprehensive Research & Development Capabilities 20
Strength - Strategic Collaborations 20
Strength - Strong Liquidity 20
Array BioPharma Inc. - Weaknesses 21
Weakness - History of Losses 21
Array BioPharma Inc. - Opportunities 21
Opportunity - Strategic Collaboration 21
Opportunity - Robust Pipeline Products 21
Opportunity - Market Potential: Cancer 21
Array BioPharma Inc. - Threats 22
Threat - Tightening of the FDA’s Regulatory Oversight 22
Threat - Competitive Landscape 22
Threat - Uncertain R&D Outcomes 22
Array BioPharma Inc. - Key Competitors 23
Section 3 – Company Financial Ratios 24
Financial Ratios - Capital Market Ratios 24
Financial Ratios - Annual Ratios 24
Performance Chart 26
Financial Performance 26
Financial Ratios - Interim Ratios 27
Financial Ratios - Ratio Charts 28
Section 4 – Company’s Lifesciences Financial Deals and Alliances 29
Array BioPharma Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 29
Array BioPharma Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 30
Array BioPharma Inc., Recent Deals Summary 31
Section 5 – Company’s Recent Developments 32
Array BioPharma Inc., Recent Developments 32
Feb 04, 2013: Array Reports Revenue Of $18.4m In Q2 Fiscal 2013 32
Oct 31, 2012: National Jewish Health Researchers Discover New Target For Treatment Of Peanut Allergy 34
Oct 29, 2012: Array Reports Revenue Of $15.8m In Q1 Fiscal 2013 34
Aug 13, 2012: Array BioPharma Reports Revenue Of $20.7m In Q4 Fiscal 2012 36
Apr 30, 2012: Array BioPharma Reports Revenue Of $19.1m In Q3 Fiscal 2012 37
Apr 26, 2012: Array BioPharma Names Ron Squarer As CEO 39
Mar 06, 2012: Foundation Medicine Announces Collaboration With Array BioPharma 39
Jan 30, 2012: Array BioPharma Elects Gwen Fyfe To Board 40
Jan 30, 2012: Array BioPharma Reports Revenue Of $23.2m In Q2 Fiscal 2012 40
Jan 16, 2012: Array BioPharma Announces Resignation Of Robert Conway As CEO 42
Section 6 – Appendix 43
Methodology 43
Ratio Definitions 43
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Array BioPharma Inc., Key Facts 5
Array BioPharma Inc., Key Employees 6
Array BioPharma Inc., Key Employee Biographies 7
Array BioPharma Inc., Major Products and Services 8
Array BioPharma Inc., Number of Pipeline Products by Therapy Area 9
Array BioPharma Inc., Number of Pipeline Products by Development Stage 10
Array BioPharma Inc., Pipeline Products By Therapy Area and Development Phase 11
Array BioPharma Inc., History 12
Array BioPharma Inc., Other Locations 17
Array BioPharma Inc., Key Competitors 23
Array BioPharma Inc., Ratios based on current share price 24
Array BioPharma Inc., Annual Ratios 24
Array BioPharma Inc., Interim Ratios 27
Array BioPharma Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 29
Array BioPharma Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 30
Array BioPharma Inc., Recent Deals Summary 31
Currency Codes 43
Capital Market Ratios 43
Equity Ratios 44
Profitability Ratios 44
Cost Ratios 45
Liquidity Ratios 45
Leverage Ratios 46
Efficiency Ratios 46

List of Figures
Array BioPharma Inc., Pipeline Products by Therapy Area 9
Array BioPharma Inc., Pipeline Products by Development Phase 10
Array BioPharma Inc., Performance Chart (2008 - 2012) 26
Array BioPharma Inc., Ratio Charts 28
Array BioPharma Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 29
Array BioPharma Inc., Pharmaceuticals & Healthcare, Deals by Type, 2007 to YTD 2013 30




...